Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells

Molecular Pharmacology

Volumn 69, Issue 3, 2006, Pages 932-940

  Ying, Zhekang ^a   Jin, Liming ^a   Palmer, Trenis ^a   Webb, R Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANGIOTENSIN II; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CALCIUM; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATE; MYOSIN LIGHT CHAIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RHO FACTOR; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; RHO KINASE; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG INHIBITION; LEUKEMIA; MALE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; UPREGULATION; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOTENSIN II; ANIMALS; BASE SEQUENCE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; MUSCLE CELLS; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION; VASODILATION;

EID: 33644836601     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.017830     Document Type: Article

References (27)

1. Booden MA, Siderovski DP, and Der CJ (2002) Leukemia-associated Rho guanine nucleotide exchange factor promotes G alpha q-coupled activation of RhoA. Mol Cell Biol 22:4053-4061.
2. Brasier AR, Jamaluddin M, Han Y, Patterson C, and Runge MS (2000) Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 212:155-169.
3. Dugourd C, Gervais M, Pierre C, and Monnot C (2003) Akt is a major downstream target of PI3-kinase involved in angiotensin II-induced proliferation. Hypertension 41:882-890.
4. Hakoshima T, Shimizu T, and Maesaki R (2003) Structural basis of the Rho GTPase signaling. J Biochem (Tokyo) 134:327-331.
5. Hart MJ, Jiang X, Kozasa T, Roscoe W, Singer WD, Gilman AG, Sternweis PC, and Bollag G (1998) Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galpha13. Science (Wash DC) 280:2112-2114.
6. Hu E and Lee D (2005) Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin Ther Targets 9:715-736.
7. Jing Q, Xin SM, Cheng ZJ, Zhang WB, Zhang R, Qin YW, and Pei G (1999) Activation of p38 mitogen-activated protein kinase by oxidized LDL in vascular smooth muscle cells: mediation via pertussis toxin-sensitive G proteins and association with oxidized LDL-induced cytotoxicity. 84:831-839.
8. Karin M (2004) Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann Rheum Dis 63 (Suppl 2):ii62-ii64.
9. Kim S and Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11-34.
10. Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, Bollag G, and Sternweis PC (1998) p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science (Wash DC) 280:2109-2111.
11. Lee DL, Webb RC, and Jin L (2004) Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 44:796-799.
12. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, and Takeshita A (2001) Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38:1307-1310.
13. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, Isaka N, Hartshorne DJ, and Nakano T (2003) Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 92:411-418.
14. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases and myosin phosphatase. Physiol Rev 83:1325-1358.
15. Swallow DM (2003) Genetics of lactase persistence and lactose intolerance. Annu Rev Genet 37:197-219.
16. Tanabe S, Kreutz B, Suzuki N, and Kozasa T (2004) Regulation of RGS-RhoGEFs by Galpha12 and Galpha13 proteins. Methods Enzymol 390:285-294.
17. Touyz RM and Schiffrin EL (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52:639-672.
18. Touyz RM (2003) The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 5:155-164.
19. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, et al. (1997) Calcium-sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature (Lond) 389:990-994.
20. 11. J Biol Chem 278:28743-28749.
21. Wang Q, Liu M, Kozasa T, Rothstein JD, Sternweis PC, and Neubig RR (2004) Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. J Biol Chem 279:28831-28834.
22. Weber DS and Webb RC (2001) Enhanced relaxation to the Rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats. Pharmacology 63:129-133.
23. Yamakawa T, Tanaka S-I, Kamei J, Kadonosomo K, and Okuda K (2003) Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Eur J Pharmacol 478:39-46.
24. Ying Z, Jin L, Dorrance AM, and Webb RC (2004) Increased expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens 17:981-985.
25. Yoneda T, Kihara Y, Takenaka H, Onozawa Y, Sarai N, and Kita T (2003) RhoA expression is not a critical determinant in hypertension evolution in salt-sensitive Dahl rats. Med Sci Monit 9:BR399-BR402.
26. Zhuo J, Allen AM, Alcorn D, Aldred GP, MacGregor DP, and Mendelsohn FAO (1995) The distribution of angiotensin II receptors, in Hypertension: Pathophysiology, Diagnosis and Management (Laragh JH and Brenner BM eds) pp 1739-1762, Raven Press Ltd., New York.
27. Ziegler-Heitbrock HW, Sternsdorf T, Liese J, Belohradsky B, Weber C, Wedel A, Schreck R, Bauerle P, and Strobel M (1993) Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol 151:6986-6993.